Cybin Inc Total Liabilities
Cybin Inc total liabilities. Based on the latest financial reports, Cybin Inc (CYBN) has total liabilities worth CA$16.18 Million CAD (≈ $11.70 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Cybin Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cybin Inc (2020–2025)
Total liabilities of Cybin Inc from 2020 to 2025. This chart illustrates how Cybin Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Cybin Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Cybin Inc Competitors by Total Liabilities
The table below lists competitors of Cybin Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NHN KCP Corp
KQ:060250
|
Korea | ₩359.08 Billion |
|
Zhengzhou Tiamaes Technology Co Ltd
SHE:300807
|
China | CN¥151.29 Million |
|
Itafos Corp
V:IFOS
|
Canada | CA$378.91 Million |
|
Jiangsu Xinning Modern Logist
SHE:300013
|
China | CN¥677.72 Million |
|
Zhejiang Hengwei Battery Co. Ltd.
SHE:301222
|
China | CN¥116.29 Million |
|
Seaport Entertainment Group Inc.
NYSE:SEG
|
USA | $129.47 Million |
|
Materialise NV
F:06MA
|
Germany | €164.14 Million |
|
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
|
USA | $12.39 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Cybin Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CYBN asset base.
Liquidity & Leverage Metrics
Cybin Inc Total Liabilities Ratios Explained
Cybin Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cybin Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cybin Inc (2020–2025)
The table below shows the annual total liabilities of Cybin Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | CA$21.42 Million ≈ $15.49 Million |
+112.14% |
| 2024-03-31 | CA$10.10 Million ≈ $7.30 Million |
+78.28% |
| 2023-03-31 | CA$5.66 Million ≈ $4.10 Million |
-28.39% |
| 2022-03-31 | CA$7.91 Million ≈ $5.72 Million |
+31.93% |
| 2021-03-31 | CA$5.99 Million ≈ $4.34 Million |
+2179.09% |
| 2020-03-31 | CA$263.00K ≈ $190.25K |
-- |
About Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more